Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Family Medicine | Nursing | Pharmacy | Psychiatry | Journal

Back to Journal Articles

Guideline-Concordant Tx Cuts Mortality in Schizophrenia

Last Updated: November 07, 2012.

 

Mortality also decreased with use of anti-Parkinson's medications, mental health visits

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For patients with schizophrenia, adherence to antipsychotic medications, as recommended by the 2009 Schizophrenia Patient Outcomes Research Team, correlates with reduced mortality, according to research published online Oct. 30 in the Schizophrenia Bulletin.

WEDNESDAY, Nov. 7 (HealthDay News) -- For patients with schizophrenia, adherence to antipsychotic medications, as recommended by the 2009 Schizophrenia Patient Outcomes Research Team (PORT), correlates with reduced mortality, according to research published online Oct. 30 in the Schizophrenia Bulletin.

Bernadette A. Cullen, M.B., B.Ch., of the Johns Hopkins School of Medicine in Baltimore, and colleagues conducted a retrospective, 10-year, cohort study to evaluate antipsychotic use in 2,132 adult Medicaid beneficiaries with schizophrenia and to determine whether adherence to guideline recommendations is associated with decreased mortality in this patient population.

The researchers found that annual antipsychotic continuity correlated with reduced mortality. Patients who had an annual continuity with their antipsychotic medication of 90 percent or higher versus those with annual medication possession rates of less than 10 percent had a significantly lower hazard ratio for mortality (0.75). Patients using first-generation antipsychotic medications equal to or greater than 1,500 chlorpromazine dosing equivalents had an increased risk of death (hazard ratio [HR], 1.88), while use of anti-Parkinson medications correlated with a significantly lower risk of death (HR, 0.72). Mental health visits also correlated with slightly, but significantly, lower mortality risk (HR, 0.96).

"Given this association between guideline adherence and reduced risk of mortality, further research should address why long-term adherence to PORT pharmacological guidelines is low among Medicaid beneficiaries with schizophrenia," the authors write. "In order to improve adherence to PORT guidelines, quality improvement programs should consider implementation of systems to routinely monitor outcomes among patients with schizophrenia."

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Triptorelin Doesn't Avert Early Ovarian Failure in Lymphoma Next: Vitamin D Levels May Be Linked to Familial Longevity

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.